Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned a consensus rating of “Hold” from the five brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $1.50.
Separately, Rodman & Renshaw assumed coverage on Nektar Therapeutics in a report on Friday, June 28th. They issued a “buy” rating and a $2.00 price target on the stock.
Read Our Latest Stock Analysis on NKTR
Nektar Therapeutics Stock Up 4.8 %
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Nektar Therapeutics had a negative return on equity of 133.64% and a negative net margin of 190.09%. The firm had revenue of $23.49 million for the quarter, compared to the consensus estimate of $17.24 million. During the same period in the prior year, the business earned ($0.27) EPS. As a group, sell-side analysts expect that Nektar Therapeutics will post -0.85 EPS for the current fiscal year.
Institutional Trading of Nektar Therapeutics
Hedge funds have recently made changes to their positions in the stock. Victory Capital Management Inc. bought a new stake in shares of Nektar Therapeutics in the 2nd quarter worth approximately $29,000. Values First Advisors Inc. bought a new stake in Nektar Therapeutics during the 2nd quarter valued at $56,000. State Board of Administration of Florida Retirement System bought a new stake in Nektar Therapeutics during the 1st quarter valued at $63,000. SG Americas Securities LLC raised its stake in Nektar Therapeutics by 63.0% during the 2nd quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 28,338 shares in the last quarter. Finally, Candriam S.C.A. bought a new stake in Nektar Therapeutics during the 2nd quarter valued at $99,000. Institutional investors own 75.88% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Recommended Stories
- Five stocks we like better than Nektar Therapeutics
- What Investors Need to Know to Beat the Market
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- How to Evaluate a Stock Before BuyingÂ
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What Are Dividend Challengers?
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.